| Comprehensive Foot Care Pllc | |
|
4100 Sion Farm Commercial Center, Suite 7, St. Croix, VI 00820 | |
| (340) 713-8397 | |
| (340) 719-5103 |
| Full Name | Comprehensive Foot Care Pllc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 4100 Sion Farm Commercial Center, St. Croix, Virgin Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427170729 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 1058 (Virgin Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Comprehensive Foot Care Pllc 4100 Sion Farm Commercial Center., Suite 7, St. Croix, VI 00820 Ph: (340) 713-8397 | Comprehensive Foot Care Pllc 4100 Sion Farm Commercial Center, Suite 7, St. Croix, VI 00820 Ph: (340) 713-8397 |
News Archive
In people with high cholesterol levels, the fat that is built up in the artery walls narrows the arteries causing a condition called atherosclerosis. A study published on 19th June in the European Heart Journal has found the likelihood of a vaccine that can immunize humans having atherosclerosis, subsequent to successful outcomes in a mouse model study. At present, phase I clinical trial has begun in patients to see the possibility of translating the study findings to humans.
The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital.
An anterior cruciate ligament tear, an injury of the knee, can be devastating to a young athlete. While the ACL can be reconstructed through surgery, there is a high risk of re-injury in patients under the age of 25.
Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing.
› Verified 8 days ago